Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.

Autor:	Maniar R; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York., Gallitano SM; Department of Dermatology, Columbia University Irving Medical Center, New York, New York., Husain S; Department of Dermatology, Columbia University Irving Medical Center, New York, New York., Moazami G; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.; Harkness Eye Center, New York, New York., Weiss MJ; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.; Harkness Eye Center, New York, New York., Shu CA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2023 Feb 09; Vol. 21 (3), pp. 232-234.
DOI:	10.6004/jnccn.2022.7084
Abstrakt:	BRAF/MEK inhibition remains standard of care for treatment of BRAF-mutated non-small cell lung cancer (NSCLC). Although common adverse events (AEs) have been reported through clinical trials and ongoing clinical practice, only a handful of reports have detailed unusual adverse events associated with these medications. This report presents a patient with BRAF-mutated NSCLC treated with dabrafenib and trametinib who experienced 2 unusual AEs-Sweet syndrome and MEK-associated retinopathy-that responded to steroid treatment. The patient was able to continue BRAF/MEK inhibition through a coordinated multidisciplinary approach. This case highlights the importance for all clinicians to recognize unusual AEs associated with BRAF/MEK inhibition, particularly in the setting of expanded use for all BRAF V600E-mutated solid tumors.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu